Drug intelligence / Profile preview

TOTUM-070

Development stage: Unknown
Lead developer: Valbiotis
Administration: Oral

Overview

TOTUM-070 is a plant-derived active substance developed by Valbiotis, specifically designed to reduce LDL-cholesterol levels in individuals with mild-to-moderate hypercholesterolemia. It is a patented combination of five plant extracts that aims to provide a non-drug alternative or complement for cardiovascular risk management. The product's efficacy was evaluated in the Phase 2 HEART clinical trial, which demonstrated a significant reduction in blood LDL-cholesterol levels compared to placebo. TOTUM-070 is positioned within the Nutrition Health space, targeting the prevention of metabolic and cardiovascular diseases through a multi-targeted approach to lipid metabolism.

Brand names: ValbiotisPRO CholesterolValbiotis PRO Cholesterol
Other names: Lipidrive

Targets

NPC1L1 (Niemann-pick C1-Like 1 transporter)

Beyond the preview

Go deeper on TOTUM-070.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TOTUM-070.

Explore the full profile